These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 12874156)

  • 1. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care.
    Yeung H; Krentz HB; Gill MJ; Power C
    AIDS; 2006 Oct; 20(16):2005-9. PubMed ID: 17053346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care].
    Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F
    Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of antiretroviral drug resistance in HIV-positive patients.
    Krentz HB; Ko K; Beckthold B; Gill MJ
    Antivir Ther; 2014; 19(4):341-8. PubMed ID: 24296618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada.
    Krentz HB; Gill MJ
    Health Policy; 2011 Dec; 103(2-3):124-9. PubMed ID: 21893362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forecasting the medical care costs of the HIV epidemic.
    Hellinger FJ
    Caring; 1992 Aug; 11(8):52-3, 55-6, 58. PubMed ID: 10119503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.
    Bozzette SA; Joyce G; McCaffrey DF; Leibowitz AA; Morton SC; Berry SH; Rastegar A; Timberlake D; Shapiro MF; Goldman DP;
    N Engl J Med; 2001 Mar; 344(11):817-23. PubMed ID: 11248159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mounting medical care cost for adult AIDS patients at the Faculty of Medicine, Siriraj Hospital: consideration for management.
    Suwanagool S; Ratanasuwan W; Techasathit W
    J Med Assoc Thai; 1997 Jul; 80(7):431-9. PubMed ID: 9277072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting.
    Purdum AG; Johnson KA; Globe DR
    AIDS Care; 2004 Aug; 16(6):767-80. PubMed ID: 15370064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical care costs for HIV-positive and AIDS patients in four hospitals in Santiago, Chile].
    Toro L; Jara C; Adauy A; Henríquez A; Trujillo F; Child R; Ortiz E
    Rev Med Chil; 1998 Feb; 126(2):218-24. PubMed ID: 9659760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costing universal access of highly active antiretroviral therapy in Benin.
    Hounton SH; Akonde A; Zannou DM; Bashi J; Meda N; Newlands D
    AIDS Care; 2008 May; 20(5):582-7. PubMed ID: 18484329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.